The functional consequences in severe and critical covid-19 survivors - A pilot study.
COVID-19
Cardiopulmonary exercise testing
Long-term effect
Pulmonary function test
Journal
Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
24
11
2021
revised:
30
06
2022
accepted:
08
07
2022
medline:
9
6
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
To perform pulmonary function tests (PFT) in severe COVID-19 survivors one and five months after hospital discharge in order to assess the lung function, as well to identify clinical characteristics and PFT parameters associated with worse cardiopulmonary exercise testing (CPET). A prospective study included 75 patients with severe form of COVID-19. PFT was conducted one and five months after hospital discharge, in addition to CPET in a second assessment. Patients with a previous history of chronic respiratory diseases were excluded from our study. One month after hospital discharge, all examined patients had diffusion lung capacity for carbon-monoxide(DLco%) below the 80% of predicted values (in mean 58%), with 40% of patients having a restrictive pattern (total lung capacity(TLC) < 80%). In a repeated assessment after five months, pathological DLco% persisted in 40% of patients, while all other PFT parameters were normal. CPET showed reduced maximum oxygen consumption during exercise testing (VO2peak%) values in 80% of patients (in mean 69%), and exercise ventilatory inefficiency in 60%. Patients with VO2peak < 60% had significantly lower values of examined PFT parameters, both one and five months after hospital discharge. Patients with VO2peak% ≥ 60% had a significantly higher increase after the second assessment for Forced expiratory volume in 1st second (FEV1%), Forced expiratory volume in 1st second and forced vital capacity ratio (FEV1/FVC), DLco% and Diffusion lung capacity for carbon monoxide corrected for alveolar volume (DLco/VA). Significant functional abnormalities, according to PFT and CPET, was present both one and five months in severe COVID-19 survivors, thus emphasizing the importance of a comprehensive follow-up including both resting and dynamic functional assessment in these patients.
Identifiants
pubmed: 36822133
pii: S2590-0412(22)00063-0
doi: 10.1016/j.resmer.2022.100947
pmc: PMC9941854
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100947Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declarations of Competing Interest None.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Curr Opin Crit Care. 2002 Aug;8(4):331-6
pubmed: 12386494
Am J Respir Crit Care Med. 2003 Mar 1;167(5):690-4
pubmed: 12493646
Antiviral Res. 2017 Jul;143:142-150
pubmed: 28390872
Lancet Respir Med. 2020 Aug;8(8):750-752
pubmed: 32422177
N Engl J Med. 2014 Jul 17;371(3):287-8
pubmed: 25014703
Thorax. 2005 May;60(5):401-9
pubmed: 15860716
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Diagnostics (Basel). 2021 Mar 12;11(3):
pubmed: 33809260
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Eur Respir J. 2004 Sep;24(3):436-42
pubmed: 15358703
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
PLoS One. 2015 Jul 28;10(7):e0133698
pubmed: 26218647
Chest. 2005 Oct;128(4):2247-61
pubmed: 16236881
J Infect. 2020 Aug;81(2):e150-e152
pubmed: 32512021
Clinics (Sao Paulo). 2011;66(6):933-7
pubmed: 21808854
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Front Physiol. 2020 Jun 25;11:659
pubmed: 32714201
Front Cardiovasc Med. 2021 Jul 20;8:691609
pubmed: 34355029
Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77
pubmed: 12524257
Influenza Other Respir Viruses. 2018 Sep;12(5):643-648
pubmed: 29676537
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893868
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
Chest. 2005 Sep;128(3):1393-400
pubmed: 16162734
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076